FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
38.23M
52.17M
32.41M
24.09M
41.27M
26.2M
22.32M
19.01M
16.2M
13.8M
Total Cash %
1.38
2.97
2.06
1.73
2.99
2.23
2.23
2.23
2.23
Receivables
445.9M
258.5M
193.03M
199.72M
147.77M
160.43M
136.68M
116.44M
99.2M
84.51M
Receivables %
16.14
14.7
12.29
14.38
10.71
13.64
13.64
13.64
13.64
Inventories
534.51M
364.68M
421.48M
363.15M
276.42M
265.98M
226.6M
193.05M
164.47M
140.12M
Inventories %
19.35
20.74
26.84
26.15
20.03
22.62
22.62
22.62
22.62
Payable
400.98M
296.77M
251.07M
287.61M
249.88M
202.7M
172.69M
147.12M
125.34M
106.78M
Payable %
14.52
16.87
15.99
20.71
18.1
17.24
17.24
17.24
17.24
Cap Ex
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
Cap Ex %
-1.22
-2.06
-1.76
-1.7
-1.71
-1.69
-1.69
-1.69
-1.69
